DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Lupron Depot PED (Leuprolide Acetate) - Published Studies


Published Studies Related to Lupron Depot PED (Leuprolide)

Well-designed clinical trials related to Lupron Depot PED (Leuprolide)

Effects of metformin and leuprolide acetate on insulin resistance and testosterone levels in nondiabetic postmenopausal women: a randomized, placebo-controlled trial. [2010]

The pharmacokinetics and pharmacodynamics of a new sustained-release leuprolide acetate depot compared to market references. [2008]

Randomized double-blind study evaluating the efficacy on uterine fibroids shrinkage and on intra-operative blood loss of different length of leuprolide acetate depot treatment before myomectomy. [2001]

Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome. [2001]

Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. [2001]

Do heavier women benefit from a higher dose of leuprolide acetate for suppression of serum estradiol? [2000]

Delayed oral estradiol combined with leuprolide increases endometriosis-related pain. [2000]

Randomized controlled trial of depot leuprolide in patients with chronic pelvic pain and clinically suspected endometriosis. Pelvic Pain Study Group. [1999]

Comparison of goserelin and leuprolide in combined androgen blockade therapy. [1998]

Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease: a double-blind, placebo-controlled, randomized study. [1998]

Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron Add-Back Study Group. [1998]

Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group. [1997]

A double-blind comparison of nafarelin and leuprolide acetate for down-regulation in IVF cycles. [1996]

Leuprolide acetate treatment and myoma arterial size. [1995]

Sustained benefits of leuprolide acetate with or without subsequent medroxyprogesterone acetate in the nonsurgical management of leiomyomata uteri. [1995]

GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Leuprolide Acetate Study Group. [1995]

Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. [1995]

Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: changes in vertebral bone mass and serum estradiol and calcitonin. [1995]

Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. [1994]

Safety, side effects and patient acceptance of the luteinizing hormone releasing hormone agonist leuprolide in treatment of benign prostatic hyperplasia. [1994]

Effect of leuprolide acetate in patients with functional bowel disease. Long-term follow-up after double-blind, placebo-controlled study. [1994]

Comparison of leuprolide acetate and human chorionic gonadotropin for the induction of ovulation in clomiphene citrate-stimulated cycles. [1994]

A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia. [1993]

Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron Endometriosis Study Group. [1993]

Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. I. Efficacy results. [1992]

Recurrence of myomas after myomectomy in women pretreated with leuprolide acetate depot or placebo. [1992]

Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group. [1991]

Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron Study Group. [1990]

Leuprolide with and without flutamide in advanced prostate cancer. [1990]

A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata. [1989]

A randomized, placebo-controlled, double-blind study evaluating leuprolide acetate depot treatment before myomectomy. [1989]

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. [1989]

Well-designed clinical trials possibly related to Lupron Depot PED (Leuprolide)

Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. [2010]

Effects of testosterone administration on nocturnal cortisol secretion in healthy older men. [2010]

Pre- versus postmenopausal age, estradiol, and peptide-secretagogue type determine pulsatile growth hormone secretion in healthy women: studies using submaximal agonist drive and an estrogen clamp. [2010]

Preservation of GHRH and GH-releasing peptide-2 efficacy in young men with experimentally induced hypogonadism. [2009]

Factors other than sex steroids modulate GHRH and GHRP-2 efficacies in men: evaluation using a GnRH agonist/testosterone clamp. [2009]

Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. [2009]

Gonadotropin-releasing hormone agonist pretreatment did not decrease postoperative adhesion formation after abdominal myomectomy in a randomized control trial. [2009]

Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. [2007]

Prevention of breast cancer: current state of the science and future opportunities. [2006]

Testosterone suppression of CRH-stimulated cortisol in men. [2005]

The effects of pharmacologically induced hypogonadism on mood in healthy men. [2004]

Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. [2004]

Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy. [2003]

Effect of gonadotropin-releasing hormone agonist and medroxyprogesterone acetate on calcium metabolism: a prospective, randomized, double-blind, placebo-controlled, crossover trial. [2003]

[Clinical effects of a 3-month formulation LH-RH agonist, TAP-144-SR (3M) in prostate cancer patients]. [Article in Japanese] [2002]

Pharmacokinetics, safety and tolerability of three dosage regimens of buccal adhesive testosterone tablets in healthy men suppressed with leuprorelin. [2002]

Impact of six months of GnRH agonist therapy for endometriosis. Is there an age-related effect on bone mineral density? [2002]

Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. [2002]

The gonadotrophin-releasing hormone antagonist ganirelix--history and introductory data. [2002]

A crossover study of triptorelin and leuprorelin acetate. [2000]

Quantification of endometriosis-associated pain and quality of life during the stimulatory phase of gonadotropin-releasing hormone agonist therapy: a double-blind, randomized, placebo-controlled trial. [2000]

Effects of gonadal steroids in women with a history of postpartum depression. [2000]

A double-blind randomised trial of leuprorelin acetate prior to hysterectomy for dysfunctional uterine bleeding. [2000]

Menopausal changes in the myometrium: an investigation using a GnRH agonist model. [1999]

Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group. [1999]

A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation. [1999]

Uterine ultrasonographic changes with gonadotropin-releasing hormone agonists. [1999]

Effects of add-back therapy on bone mineral density and pyridinium crosslinks in patients with endometriosis treated with gonadotropin-releasing hormone agonists. [1999]

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. [1998]

Depressive symptoms associated with gonadotropin-releasing hormone agonists. [1998]

A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata. [1998]

Steroidal 'add-back' therapy in patients treated with GnRH agonists. [1998]

Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. [1998]

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. [1997]

Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists. [1997]

Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. [1997]

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group. [1996]

Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. [1996]

A randomized, placebo-controlled study on the effect of cyclic intermittent etidronate therapy on the bone mineral density changes associated with six months of gonadotropin-releasing hormone agonist treatment. [1996]

Dexamethasone during ovulation induction for in-vitro fertilization: a pilot study. [1996]

Morphometry of benign prostatic hyperplasia during androgen suppressive therapy. Relationships among epithelial content, PSA density, and clinical outcome. [1996]

A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group. [1996]

Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group. [1996]

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group. [1995]

The use of flutamide in hormone-refractory metastatic prostate cancer. [1993]

The concentrations of collagen-associated amino acids are higher in GnRH agonist-treated uterine myomas. [1993]

An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double blind, placebo-controlled, crossover trial. [1993]

Total androgen blockade: the United States experience. [1993]

Controversies in the treatment of metastatic prostate cancer. [1992]

National Cancer Institute study of luteinizing hormone-releasing hormone plus flutamide versus luteinizing hormone-releasing hormone plus placebo. [1991]

Decreased prolactin secretion by explant cultures of fibroids from women treated with a gonadotropin-releasing hormone agonist. [1990]

Luteinizing hormone releasing hormone agonists: the US experience. [1990]

Other research related to Lupron Depot PED (Leuprolide)

36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty. [2014]

Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial. [2013]

Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer. [2013]

Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. [2012]

Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. [2012]

Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer. [2011]

A randomized trial of microdose leuprolide acetate protocol versus luteal phase ganirelix protocol in predicted poor responders. [2011]

Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. [2011]

Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. [2010]

Other possibly related research studies

Selective estrogen receptor modulators (SERMs) for uterine leiomyomas. [2012]

Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. [2012]

Effects of progressive muscular relaxation training on anxiety, depression and quality of life of endometriosis patients under gonadotrophin-releasing hormone agonist therapy. [2012]

Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. [2011]

Radiotherapy and short-term androgen deprivation for localized prostate cancer. [2011]

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation. [2011]

Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. [2010]

Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. [2010]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017